Last reviewed · How we verify
Placebo (Ambrisentan-matching) — Competitive Intelligence Brief
phase 3
Pulmonary Arterial Hypertension
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo (Ambrisentan-matching) (Placebo (Ambrisentan-matching)) — Assistance Publique - Hôpitaux de Paris. This is a placebo control matching the appearance and administration of ambrisentan, an endothelin receptor antagonist, with no active pharmacological effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo (Ambrisentan-matching) TARGET | Placebo (Ambrisentan-matching) | Assistance Publique - Hôpitaux de Paris | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo (Ambrisentan-matching) CI watch — RSS
- Placebo (Ambrisentan-matching) CI watch — Atom
- Placebo (Ambrisentan-matching) CI watch — JSON
- Placebo (Ambrisentan-matching) alone — RSS
Cite this brief
Drug Landscape (2026). Placebo (Ambrisentan-matching) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-ambrisentan-matching. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab